

---

# Diversity of Influenza A(H5N1) Viruses in Infected Humans, Northern Vietnam, 2004–2010

Hiroataka Imai,<sup>1</sup> Jorge M. Dinis,<sup>1</sup> Gongxun Zhong, Louise H. Moncla, Tiago J.S. Lopes, Ryan McBride, Andrew J. Thompson, Wenjie Peng, Mai thi Q. Le, Anthony Hanson, Michael Lauck, Yuko Sakai-Tagawa, Shinya Yamada, Julie Eggenberger, David H. O'Connor, Yasuo Suzuki, Masato Hatta, James C. Paulson, Gabriele Neumann, Thomas C. Friedrich, Yoshihiro Kawaoka

Influenza viruses exist in each host as a collection of genetically diverse variants, which might enhance their adaptive potential. To assess the genetic and functional diversity of highly pathogenic avian influenza A(H5N1) viruses within infected humans, we used deep-sequencing methods to characterize samples obtained from infected patients in northern Vietnam during 2004–2010 on different days after infection, from different anatomic sites, or both. We detected changes in virus genes that affected receptor binding, polymerase activity, or interferon antagonism, suggesting that these factors could play roles in influenza virus adaptation to humans. However, the frequency of most of these mutations remained low in the samples tested, implying that they were not efficiently selected within these hosts. Our data suggest that adaptation of influenza A(H5N1) viruses is probably stepwise and depends on accumulating combinations of mutations that alter function while maintaining fitness.

Highly pathogenic avian influenza (HPAI) A(H5N1) viruses are not readily transmitted among humans, although a few cases of human-to-human transmission have been reported (1–3). However, recent laboratory experiments have demonstrated that a small number of amino acid changes can render avian H5 influenza viruses transmissible via respiratory droplets among ferrets (4–6) or guinea pigs (7). The evolutionary processes by which influenza A(H5N1) viruses might adapt to mammals are poorly understood. Because of error-prone genome

replication, influenza viruses exist in an infected host as a collection of genetic variants; this within-host genetic diversity is believed to facilitate rapid adaptation to changing selective pressures (8). Recent mathematical models have highlighted the role of virus mutation rates, the number of replication cycles in a given host, and natural selection in assessing the likelihood with which an influenza A(H5N1) virus transmissible among mammals might emerge, but little information on avian influenza virus diversity within infected hosts was available to inform these studies (9,10).

We recently found that selection pressure on hemagglutinin (HA) can impose a strong population bottleneck during virus transmission: a variant representing only 5.9% of the total virus population in animals infected with a reassortant influenza A(H5N1) virus infected an animal via aerosol transmission (11). These findings prompted us to seek a deeper understanding of virus populations in infected humans. We used deep-sequencing and functional analyses to evaluate the genetic and functional diversity among influenza A(H5N1) viruses in infected humans.

## Materials and Methods

### Biosafety and Biosecurity

The studies were conducted after the University of Wisconsin–Madison Office of Biologic Safety completed risk assessments for the proposed experiments and the Institutional Biosafety Committee approved the experiments. All experiments used the biosafety and biosecurity practices and procedures that were developed in conjunction with the University's Select Agent Program and approved by the Centers for Disease Control and Prevention Division of Select Agents and Toxins and by the US Department of Agriculture, Animal and Plant Health Inspection Service, Agriculture Select Agent Services. The studies and subsequent data were reviewed for potential dual use research of concern in accordance with the US Government Policy for Oversight of Life

---

Author affiliations: University of Wisconsin, Madison, Wisconsin, USA (H. Imai, J.M. Dinis, G. Zhong, L.H. Moncla, T.J.S. Lopes, A. Hanson, M. Lauck, J. Eggenberger, D.H. O'Connor, M. Hatta, G. Neumann, T.C. Friedrich, Y. Kawaoka); The Scripps Research Institute, La Jolla, California, USA (R. McBride, A.J. Thompson, W. Peng, J.C. Paulson); National Institute of Hygiene and Epidemiology, Hanoi, Vietnam (M.t.Q. Le); University of Tokyo, Tokyo, Japan (Y. Sakai-Tagawa, S. Yamada, Y. Kawaoka); Chubu University, Kasugai, Japan (Y. Suzuki)

DOI: <https://doi.org/10.3201/eid2407.171441>

<sup>1</sup>These authors contributed equally to this article.

Sciences Dual Use Research of Concern. All experiments conducted in laboratories at the University of Tokyo (Tokyo, Japan) were approved by the appropriate committees at the University of Tokyo. Isolation and amplification of HPAI A(H5N1) viruses from clinical specimens were performed in enhanced Biosafety Level 3 laboratories at the University of Tokyo, which are approved for such use by the Ministry of Agriculture, Forestry, and Fisheries, Japan.

### RNA Extraction, cDNA Synthesis, and PCR Amplification

We obtained clinical specimens (throat swabs and tracheal aspirates) from 7 patients infected with influenza A(H5N1) virus in northern Vietnam during 2004–2010. To avoid the emergence of mutations during virus amplification in cultured cells, we extracted total RNA directly from clinical specimens by using the QIAamp MinElute Virus Spin Kit (QIAGEN, Hilden, Germany). Because of the limited amounts of viral RNA (vRNA), we reverse transcribed vRNA segments encoding known determinants of mammalian adaptation or transmissibility (i.e., polymerase basic [PB] 2, PB1, polymerase acidic [PA], nucleoprotein [NP], HA, and nonstructural [NS] segments) by using SuperScript III (Invitrogen, Carlsbad, CA, USA). We PCR amplified the segments by using iProof High-Fidelity DNA polymerase (Bio-Rad, Hercules, California, USA) with primers specific for the terminal sequences of each vRNA segment. If we failed to PCR amplify the full-length vRNAs, we used primers specific for the internal sequences (online Technical Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/24/7/17-1441-Techapp1.pdf>).

### Illumina MiSeq Sequencing

We quantified PCR-amplified and agarose gel-purified PCR products by using the Qubit dsDNA High Sensitivity Assay Kit (Invitrogen). Amplified genes were pooled, and sample barcodes were added by using the Nextera XT DNA Sample Preparation Kit (Illumina, San Diego, CA, USA). Barcoded samples were pooled in equimolar amounts and loaded onto a 500-cycle kit for sequencing on the Illumina MiSeq. Illumina MiSeq fastq files are publicly available in the Sequence Read Archive (<https://www.ncbi.nlm.nih.gov/sra>; SRA: SRP103022).

### Computational Methods

We imported Illumina MiSeq sequences into CLC Genomics Workbench version 7.3 (CLC bio, Aarhus, Denmark) in fastq format. We trimmed reads by using a quality-limit threshold of 0.001 and retained only reads  $\geq 100$  bp. Trimmed reads were de novo assembled to generate a consensus sequence for each gene segment of each patient sample. We then used these within-host consensus sequences, defined by the nucleotides found in more than half of the sequence reads at each position, as reference

sequences for further mapping. Reads were remapped to each sample's own consensus sequence to identify within-host single-nucleotide polymorphisms (SNPs), requiring that nucleotide positions be covered by  $\geq 100$  sequence reads, that they have a central base quality score  $\geq Q30$ , and that SNPs be detected in at least 1 forward and 1 reverse read. We only considered SNPs present in  $\geq 1\%$  of sequence reads within a population; we previously showed that this stringent cutoff excludes false-positive SNPs generated by using our approach (11). Amino acid variations in HA were mapped onto the A/Vietnam/1203/2004 (H5N1) HA structure (Protein Data Bank accession no. 2FK0) by using Pymol (<http://www.pymol.org>).

### Cells

MDCK cells (ATCC, Manassas, VA, USA) were maintained in minimal essential medium with 5% newborn calf serum. Human embryonic kidney 293T cells (ATCC) were maintained in Dulbecco modified Eagle medium with 10% fetal calf serum. Both cell lines were cultured at 37°C in 5% CO<sub>2</sub>.

### Viruses

Reassortants possessing an HA polymorphism in the genetic background of the respective H5 HA gene and the remaining genes derived from A/California/04/2009 (H1N1) (CA04) were generated in 293T cells by using reverse genetics (12) and amplified in MDCK cells; the resulting viruses are referred to as in the following example: CA04/UT3040I-HA-138V. Sanger sequence analysis of all virus stocks revealed that the CA04/UT36282I/II-HA-138V virus possessed a mixture of valine and alanine at HA position 138 and that the HA-203P residue of CA04/UT31312III-HA-203P was replaced by leucine. We were unable to rescue the CA04/UT31413II-HA-486H reassortant virus and therefore omitted it from further studies. Because of the research pause imposed on certain gain-of-function studies (<http://www.phe.gov/s3/dualuse/Documents/gain-of-function.pdf>), we were not able to generate 1 variant (CA04/UT31413II-HA-511I) and therefore will not discuss it further. All experiments with infectious viruses possessing the H5 HA with a polybasic cleavage site were performed in enhanced Biosafety Level 3 containment laboratories.

### Solid-Phase Binding Assay

We coated 96-well plates with sodium salts of sialylglycopolymers (poly-l-glutamic acid backbones containing N-acetylneuraminic acid linked to galactose through either an  $\alpha 2,3$  [Neu5Ac $\alpha 2,3$ Gal $\beta 1,4$ GlcNAc $\beta 1$ -Pap] or an  $\alpha 2,6$  [Neu5Ac $\alpha 2,6$ Gal $\beta 1,4$ GlcNAc $\beta 1$ -Pap] bond) (13), synthesized at Chubu University. We assessed virus binding to the sialylglycopolymers as previously described (4,14).

### Glycan Arrays

We performed glycan array analysis as previously described (15,16). Viruses were amplified in MDCK cells and inactivated by mixing the supernatants with 0.1%  $\beta$ -propiolactone (final concentration). A complete list of glycans on the array is provided in online Technical Appendix Figure 1.

### Virus Tissue Binding Assay

We diluted inactivated viruses with phosphate-buffered saline to equal amounts of viral M1 protein (as assessed by Western blot). Diluted viruses were labeled with FITC isomer I (Life Technologies, Carlsbad, CA, USA). Virus binding to human adult normal trachea sections was assessed as previously described (17,18).

### Thermostability Assay

We diluted amounts of virus equivalent to 64 hemagglutinating units in minimal essential medium supplemented with 0.3% bovine serum albumin and heat treated the diluted virus samples at 55°C for the indicated times. We then determined the hemagglutination activity of the heat-treated viruses by using HA assays with 0.5% turkey red blood cells (Rockland Immunochemicals Inc., Limerick, PA, USA). Virus infectivity was determined by performing plaque assays in MDCK cells.

### Mini-Replicon Assay

We transfected human 293T cells with pCAGGS plasmids (19) encoding wild-type or mutant PB2, PB1, PA, and NP protein with a plasmid expressing the firefly luciferase gene from a virus-like RNA (pPolWSNNA F-Luc) (20) and with the control plasmid pGL4.74[hRluc/TK] (expressing *Renilla* luciferase; Promega, Madison, WI, USA) by using TransIT293 (Mirus, Madison, WI, USA). Cells were incubated at 33°C or 37°C for 24 h and then lysed with 1× Passive Lysis Buffer (Promega). We determined luciferase activity by using the Dual-Luciferase Reporter Assay System (Promega).

### Interferon Reporter Assays

We assessed the effect of NS1 amino acid changes on interferon production as previously described (21,22) with some modifications. We transfected human 293T cells with pCAGGS plasmids expressing wild-type or mutant NS1 and with a plasmid expressing luciferase under the control of the interferon- $\beta$  promoter (pGL-interferon $\beta$  luc) (23). Luciferase activity was determined 24 h after treating cells with  $10^6$  focus-forming units of Sendai virus to induce interferon production (21,22).

To assess the effect of NS1 on interferon signaling, we transfected 293T cells with a plasmid encoding wild-type or mutant NS1 and a plasmid encoding luciferase under the control of an interferon-stimulated response element

(pISRE-Luc; Clontech, Kusatsu, Japan). Luciferase activity was determined after treating cells with human interferon- $\beta$ 1a (PBL Assay Science, Piscataway, NJ, USA).

### Statistical Analyses

For the mini-replicon assay, we used the Dunnett test to compare the viral polymerase activity of each mutant with that of the respective majority variant in each experiment. In the interferon reporter assays, we analyzed the data by using a one-way analysis of variance, followed by the Tukey post hoc test to compare the interferon antagonistic properties among the empty vector, UT36250I-NS1, and UT36250I-NS1-124M.

## Results

### Genetic Diversity of Influenza A(H5N1) Viruses in Humans

For each of the 7 patients with confirmed influenza A(H5N1) virus infection, 2–3 samples were available that had been collected on different days or from different anatomic sites (i.e., throat swabs or tracheal aspirates) (Table). To estimate the genetic diversity of these viruses in humans, we first defined a within-host consensus sequence for each viral gene segment, the sequences of which we obtained by deep sequencing with RNA extracted from patient clinical samples. We then counted the SNPs relative to this consensus that were detected at  $\geq 1\%$  frequency within each host, detecting a total of 251 nonsynonymous and 146 synonymous mutations (online Technical Appendix Table 2). Within-host genetic diversity varied considerably among patients, anatomic site of sample (nasal swab or tracheal aspirate), and day of isolation (online Technical Appendix Figure 2, Table 3). Nonetheless, 91 variants were detected  $\geq 2$  times in samples from the same patient.

Previously, we demonstrated that a viral variant detected at a frequency of only 5.9% in 1 ferret founded infection after respiratory droplet transmission to a contact ferret (11). Therefore, we focused our functional analyses on mutants present in  $\geq 5\%$  of the virus population, yielding 29 nonsynonymous polymorphisms in the viral HA, PB2, PB1, PA, NP, and NS1 proteins of viruses obtained from 6 patients (Figure 1; online Technical Appendix Table 3). One more variant (PA-85T/M) was detected at a frequency of  $< 5\%$  at the first time point, but its frequency had increased greatly by the second time point; therefore, we included this variant in our subsequent analyses, for a total of 30 variants examined (Figure 1; online Technical Appendix Table 3).

### Receptor-binding Specificity of HA Variants

Several of the HA sequence polymorphisms detected were located in the vicinity of the receptor-binding pocket (Figure 2, panel A). We therefore tested the receptor-binding

**Table.** Characteristics of patients infected with influenza A(H5N1) virus and samples collected, northern Vietnam, 2004–2010\*

Patient no., virus isolated	HA clade	Sample	Date			Outcome
			Symptom onset	Hospitalization	Sample collection	
<b>UT3040</b>						
A/Vietnam/UT3040I/2004 (UT3040I)	1	TS	NA	NA	2004 Jan 6	Died
A/Vietnam/UT3040II/2004 (UT3040II)	1	TA	NA	NA	2004 Jan 7	Died
<b>UT31312</b>						
A/Vietnam/UT31312I/2007 (UT31312I)	2.3.4	TA	NA	NA	2007 Jul 25	Died
A/Vietnam/UT31312II/2007 (UT31312II)	2.3.4	TA	NA	NA	2007 Jul 26	Died
A/Vietnam/UT31312III/2007 (UT31312III)	2.3.4	TS	NA	NA	2007 Jul 25	Died
<b>UT31394</b>						
A/Vietnam/UT31394I/2008 (UT31394I)	2.3.4	TS	NA	NA	2008 Jan 17	Died
A/Vietnam/UT31394II/2008 (UT31394II)	2.3.4	TA	NA	NA	2008 Jan 17	Died
<b>UT31413</b>						
A/Vietnam/UT31413I/2008 (UT31413I)	2.3.4	TS	2008 Feb 3	NA	2008 Feb 13	Died
A/Vietnam/UT31413II/2008 (UT31413II)	2.3.4	TA	2008 Feb 3	NA	2008 Feb 13	Died
<b>UT36250</b>						
A/Vietnam/UT36250I/2010 (UT36250I)	2.3.4.2	TS	2010 Mar 5	2010 Mar 10	2010 Mar 10	Survived
A/Vietnam/UT36250II/2010 (UT36250II)	2.3.4.2	TA	2010 Mar 5	2010 Mar 10	2010 Mar 11	Survived
<b>UT36282</b>						
A/Vietnam/UT36282I/2010 (UT36282I)	2.3.4.1	TS	2010 Mar 27	2010 Apr 2	2010 Apr 1	Survived
A/Vietnam/UT36282II/2010 (UT36282II)	2.3.4.1	TS	2010 Mar 27	2010 Apr 2	2010 Apr 3	Survived
<b>UT36285</b>						
A/Vietnam/UT36285I/2010 (UT36285I)	2.3.4.1	TS	2010 Apr 2	2010 Apr 4	2010 Apr 4	Survived
A/Vietnam/UT36285II/2010 (UT36285II)	2.3.4.1	TS	2010 Apr 2	2010 Apr 4	2010 Apr 8	Survived

\*HA, hemagglutinin; NA, not available; TA, throat swab; TS, tracheal aspirate.

properties of these variants by using a solid-phase binding assay with synthetic  $\alpha$ 2,3- or  $\alpha$ 2,6-linked sialylglycopolymers (Figure 2, panels B–O). A virus possessing the HA gene from the human A/Kawasaki/173/2001 (H1N1) virus and the remaining genes from CA04 (CA04/K173) served as a control virus for human virus receptor-binding specificity. As expected, this virus preferentially bound to  $\alpha$ 2,6-linked sialylglycopolymers (Figure 2, panel B). In contrast, CA04-reassortant H5 viruses encoding the majority and minority variants from infected persons preferentially bound to avian-type  $\alpha$ 2,3-linked sialylglycopolymers (Figure 2, panels C–O). In the context of CA04/UT3040II-HA, the HA-186K variant bound more efficiently to human-type receptors than did consensus CA04/UT3040II (encoding HA-186N) (Figure 2, panels C and E); however, this effect was not detected with the same viruses in the glycan arrays (Figure 3, panels A, C), or when we tested the same mutation in UT31312III HA (Figure 2, panels F, G). Therefore, more rigorous evaluation is needed to assess the role of 186K in human-type receptor specificity.

We also performed a glycan array analysis on an array containing 135 synthetic glycans representing O-linked and N-linked glycans and linear glycan fragments with sialic acid in  $\alpha$ 2,3- and  $\alpha$ 2,6-linkages (online Technical Appendix Figure 1) (15). Glycan arrays can be used to evaluate the specificity of viruses for numerous glycans simultaneously and to assess avian- and human-type specificity with high stringency; however, they are less effective for assessing changes in avidity (24). Tested wild-type and mutant influenza A(H5N1) viruses interacted primarily with  $\alpha$ 2,3-linked glycans (Figure 3, panels

A–G); however, some mutations affected the binding intensity to receptor glycans (e.g., compare Figure 3, panels F and G). Two human control viruses (CA04/K173 and A/Brisbane/10/2007) that we used in previous assays bound primarily to  $\alpha$ 2,6-linked glycans (Figure 3, panels H, I). Collectively, these data demonstrate that the H5 HA variants detected in infected humans retained their preferential binding to avian-type receptors.

#### Binding of HA Variants to Human Respiratory Tissues

We also tested the HA variants for their ability to bind to human respiratory airway samples (online Technical Appendix Figure 3). The human CA04/K173 virus bound extensively to epithelial cells of tracheal tissue cross-sections. The CA04/UT3040I/II-HA virus bound weakly to mucus secreted by goblet cells but not to epithelial cells. Unlike the results of our solid-phase binding assays, CA04/UT36250I/II-HA-138V, CA04/UT36282I/II-HA, and CA04/UT36282I/II-HA-138V/A displayed appreciable binding to epithelial cells in human tracheal tissues (online Technical Appendix Figure 3). To confirm virus binding specificity to sialic acids, we pretreated the tracheal tissues with *Arthrobacter ureafaciens* neuraminidase, which removes terminal sialic acids; as expected, virus binding to these samples was greatly reduced (online Technical Appendix Figure 4). The remaining viruses displayed little to no binding to tracheal epithelial cells. These findings show that although we detected polymorphisms at HA amino acid positions known to affect receptor binding, the variants tested did not acquire preferential binding to human-type receptors, although the HA-138V mutation in UT36250I



**Figure 1.** Frequencies of nonsynonymous single-nucleotide polymorphisms detected in  $\geq 5\%$  of sequence reads obtained from humans infected with influenza A(H5N1) virus, northern Vietnam, 2004–2010. Bar graphs depict the percentages of the indicated single-nucleotide polymorphisms from TS or TA samples. The amino acids at the respective positions are shown by the single-letter code. HA-54(+1) refers to an H5 HA amino acid insertion after position 54 that was not found in H3 HAs (which was used as a reference for the numbering of HA amino acid positions). HA, hemagglutinin; NP, nucleocapsid; NS, nonstructural; PA, polymerase acidic; PB, polymerase basic; TA, tracheal aspirate; TS, throat swab.

and the HA-138V/A mutation in UT36282I/II enhanced HA binding to epithelial cells in human respiratory tissue.

### Stability of HA Variants


We (4) and others (25) have shown that increased HA stability is needed for the respiratory droplet transmissibility of H5 viruses among ferrets. We therefore tested the HA polymorphisms that were located away from the receptor-binding domain (Figure 4, panel A) for their effect on HA thermostability (Figure 4, panels B–G). The selected variants were incubated at 55°C for the indicated time intervals, after which loss of infectivity was determined by means of a plaque assay and HA hemagglutination activity by hemagglutination assay.

The human CA04/K173 virus displayed appreciably higher thermostability than the avian control virus CA04/VN1203 (possessing the A/Vietnam/1203/2004 [H5N1] HA gene in the genetic background of CA04). No appreciable


differences in thermostability were detected between the minority and majority variants in CA04/UT31312I/III (Figure 4, panels B, E) and in CA04/UT31394I/II (Figure 4, panels C, F) except that CA04/UT31394II-HA-67T lost hemagglutination activity more rapidly than the other variants for unknown reasons. We did not, therefore, identify HA-stabilizing mutations that arose during replication in humans.

### Polymerase Activity of Polymerase and NP Variants

Amino acid variations were located in multiple domains of each polymerase subunit. Our mini-replicon assay demonstrated that PB2-627K conferred significantly higher polymerase activity in mammalian cells than did PB2-627E (Figure 5), as demonstrated previously by us (26) and others (25). In addition, the UT36250I PB1-598P minority variant showed an  $\approx 80$ -fold increase in polymerase activity at 37°C, but not at 33°C, relative to the PB1-598L majority variant (Figure 5, panels A and B). These potentially



**Figure 2.** Effect of amino acid variations in hemagglutinin (HA) on influenza virus receptor binding specificities in influenza A(H5N1) virus isolates from humans, northern Vietnam, 2004–2010. A) Localization of selected amino acid variations detected in clinical samples. The detected HA changes were mapped onto the receptor-binding domain (aa positions 117–265) of a monomer of A/VN1203/2004 (H5N1) HA (Protein Data Bank accession no. 2FK0). Red indicates modeled human-type receptor; blue indicates positions of amino acid variations on the receptor-binding domain. B–O) Receptor-binding specificities of HA variants. Direct binding of virus to  $\alpha$ 2,3-linked (blue) or  $\alpha$ 2,6-linked (red) sialylglycopolymers was assessed. Shown is the mean receptor-binding specificity + SDs of triplicates of a single experiment. If 2 isolate numbers are listed (e.g., CA04/UT3040I/II), we tested the major sequence variant (which is identical between the 2 samples: B) CA04/K173; C) CA04/UT3040I/II-HA; D) CA04/UT3040I-HA-138V; E) CA04/UT3040II-HA-186K; F) CA04/UT31312III-HA; G) CA04/UT31312III-HA-186K; H) CA04/UT31312III-HA-203P-to-L (the proline residue introduced at position 203 of UT31312III HA mutated to leucine); I) CA04/UT31394II-HA; J) CA04/UT31394II-HA-207T; K) CA04/UT36250I/II-HA; L) CA04/UT36250I/II-HA-138V; M) CA04/UT36250II-HA-226K; N) CA04/UT36282I/II-HA; O) CA04/UT36282I/II-HA-138V/A (after introduction of valine at position 138 of UT36282I/II HA, we detected both valine and alanine at this position).



**Figure 3.** Glycan microarray analysis of selected influenza A(H5N1) virus isolates from humans, northern Vietnam, 2004–2010. The labeled viruses were applied to a microarray that included  $\alpha$ 2,3-linked (blue) and  $\alpha$ 2,6-linked (red) glycans, which are indicated by numbers on the x-axis (online Technical Appendix Figure 1, <https://wwwnc.cdc.gov/EID/article/24/7/17-1441-Techapp1.pdf>). Shown are the binding signals with error bars reflecting SEMs calculated from 4 of 6 replicates on the array after discarding the highest and lowest signals; note that the scales on the y-axis (relative fluorescence) vary because of differences in binding strength: A) CA04/UT3040I/II-HA; B) CA04/UT3040I-HA-138V; C) CA04/UT3040II-HA-186K; D) CA04/UT36250I/II-HA; E) CA04/UT36250I/II-HA-138V; F) CA04/UT36282I/II-HA; G) CA04/UT36282I/II-HA-138V/A; H) CA04/K173; I) Brisbane/10/2007.


advantageous mutations did not become dominant in some of the samples available for this study; however, we cannot know whether these mutations became dominant at later times for which samples are not available. Two mutations (PA-85M and PA-417V) occurred at a low frequency in UT3040I yet represented the only population in UT3040II. Of note, both mutations reduced polymerase activity at 1 or both temperatures tested (Figure 5).

In summary, we detected a complex pattern of phenotypic effects of avian virus polymerase complex mutations in infected humans. With the exception of PB2-627K, some mutations improved polymerase activity in mini-replicon assays but did not become dominant in the virus samples tested, whereas other mutations replaced the wild-type

amino acid although they appeared to reduce polymerase activity *in vitro*. Thus, enhancement of polymerase activity in the mini-replicon assay did not necessarily correlate with mutations that became dominant *in vivo*.

#### Interferon-antagonistic Activity of NS1 Variants

The influenza A virus NS gene encodes 2 proteins, 1 of which (NS1) counteracts host innate interferon responses (27). HPAI A(H5N1) viruses are relatively resistant to the antiviral effects of host interferon responses (28), which might, in part, result from specific point mutations in the NS1 proteins of some of these viruses (29). We detected only 1 nonsynonymous polymorphism in NS1, a methionine (minority variant) or isoleucine (majority variant) at



**Figure 4.** Effect of amino acid variations in HA on virus thermostability in influenza A(H5N1) virus isolates from humans, northern Vietnam, 2004–2010. A) Amino acid substitutions in non-receptor-binding domains mapped on the 3-dimensional structure of the monomer of VN1203 HA (Protein Data Bank accession no. 2FK0). Red indicates modeled human-type receptor; purple indicates positions of amino acid variations on the non-receptor-binding domains; blue indicates positions of amino acid variations on the receptor-binding domain corresponding to Figure 2, panel A. B–G) Thermostability of HA variants depicted in panel A. Amounts of viruses equivalent to 64 HA units were incubated at 55°C for 15, 30, 60, 120, and 240 min. B–D) HA titers in heat-treated samples were determined by performing HA assays with 0.5% turkey red blood cells: B) CA04/UT31312II-HA, CA04/UT31312II-HA-92K, CA04/UT31312III-HA, CA04/VN1203; C) CA04/UT31394II-HA, CA04/UT31394II-HA-54(+1)E, CA04/UT31394II-HA-67T, CA04/VN1203; D) CA04/K173. E–G) Virus titers of heat-treated samples determined by means of plaque assays in MDCK cells. Shown are the mean HA or virus titers of triplicates from a single experiment. Dashed lines indicate the detection limit for virus titration (20 PFU/mL). E) CA04/UT31312II-HA, CA04/UT31312II-HA-92K, CA04/UT31312III-HA, CA04/VN1203; F) CA04/UT31394II-HA, CA04/UT31394II-HA-54(+1)E, CA04/UT31394II-HA-67T, CA04/VN1203; G) CA04/K173. CA04/K173 virus was used as a control. HA, hemagglutinin.

position 124 of NS1 in samples UT36250I and UT36250II (Figure 1); the frequency of the NS1-124M minority variant increased slightly in samples collected on consecutive days. We compared the ability of both NS1 variants to interfere with interferon production and signaling. The UT36250I-NS1 (encoding the NS1-124I majority variant) and UT36250I-NS1-124M proteins showed similar ability to antagonize interferon production (online Technical Appendix Figure 5, panel A). However, UT36250I-NS1-124M was slightly more efficient than UT36250I-NS1 at suppressing interferon signaling (online Technical Appendix Figure 5, panel B). This finding might explain the slightly increased frequency of NS1-124M on the second day of sampling, although such slight differences in variant frequency and interferon signaling suppression might not be biologically significant.


## Discussion

Worldwide, HPAI A(H5N1) viruses have infected  $\approx 850$  persons but have yet to adapt to humans. Because viral genetic and phenotypic diversity might facilitate adaptation in infected persons, we performed deep-sequencing and functional assays for influenza A(H5N1) viruses isolated from humans. We had access to only throat swab and tracheal aspirate samples; virus populations in other anatomic sites, such as alveoli, might differ. Nonetheless, the virus

populations we observed were diverse, but most variants were detected only transiently, at low frequencies, or both, including variants with potentially beneficial traits (e.g., the PB1-598P mutation).

We found only a few sequence variants in  $>1$  patient; they included PB2-627E/K, HA-138A/V, and HA-186N/K. PB2-627K is a known determinant of mammalian adaptation that increases the replicative ability of avian influenza virus polymerase complexes in mammals (26, 30, 31). Despite its strong effect on adaptation in mammals, in some samples, it coexisted with PB2-627E (Figure 1). Similarly, HA-138V and HA-186K, which can increase binding to human-type receptors (14, 32–34), were detected in 3 and 2 patient samples, respectively. Although the HA-186K mutation exhibited increased binding to human-type receptors for 1 strain in the sialylglycopolymer binding assay, it did not alter the overall avian-type receptor specificity of the variants assessed by the glycan arrays, and both HA-138V and HA-186K coexisted with other viral variants in the samples tested. All variants bound to a wide variety of avian-type receptors, with no clear differences in specificity. Besides PB2-627K, the PB1-598P minority variant conferred a sizable increase in polymerase activity when compared with the majority population (encoding PB1-598L) (Figures 1, 5). Position 598 of PB1 lies in the so-called thumb domain of PB1 (35),





**Figure 5.** Effect of amino acid variations in polymerases and NP on viral polymerase activity in influenza A(H5N1) virus isolates from humans, northern Vietnam, 2004–2010. 293T cells were transfected with plasmids encoding the viral replication complex (PB2, PB1, PA, and NP), with a plasmid for the expression of an influenza virus mini-genome that encodes the firefly luciferase gene, and with a plasmid encoding *Renilla* luciferase (transfection control). If 2 or 3 isolate numbers are listed, we tested the major sequence variant, which is identical among the samples. The cells were incubated at 33°C (A) or at 37°C (B) for 24 h, and firefly and *Renilla* luciferase activities were measured by use of the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). The firefly luciferase values were divided by the *Renilla* luciferase values to normalize for variances in transfection efficiency. The experiments (each in triplicate) were independently repeated twice. The mean relative viral polymerase activities plus SDs of each independent experiment are shown as black and white bars. The viral polymerase activity of the respective majority variant was set to 100%. NP, nucleocapsid; PA, polymerase acidic; PB, polymerase basic; \* $p < 0.05$ ; \*\* $p < 0.01$  (both by Dunnett test).

and the amino acid at this position might interact with the PA polymerase subunit. We do not know how the L-to-P change would affect influenza virus replication; mechanistic follow-up studies will be necessary to answer this question. There was no clear association between particular virus mutations and clinical outcomes of patients in this study. Indeed, even the PB2-627K mutation was not always detected in patients who died (e.g., patient UT31413).

The evolutionary forces that govern mammalian adaptation and the emergence of viruses capable of transmission among humans are largely unknown. RNA virus replication generates within-host genetic diversity that can rapidly change because of selective pressures (36,37). One might assume that in infected humans, positive selection favors the rapid outgrowth of variants that possess mammalian-type traits and that variants with human-adapting mutations might commonly be found as subpopulations within infected persons even if they were not present in most viruses. However, we detected few variants with such traits; only the known mammalian-adapting PB2-627K substitution

became dominant in several virus populations. These findings might imply that for a variant to become dominant, additional potentiating mutation(s) are necessary within the same genetic background as the adapting mutation. In other words, adaptive mutations might alter virus phenotypes but might require the presence of potentiating mutations to maintain viral fitness. For instance, we (4) and others (25) have shown the crucial role of another phenotypic trait, increased HA stability, for the respiratory droplet transmissibility of H5 viruses among mammals. Thus, avian influenza virus adaptation to humans probably does not occur in a steady linear fashion; rather, it probably depends on the stepwise accumulation of potentiating mutations that favor the emergence of a particular adaptive mutation, followed by the accumulation of additional potentiating mutations that favor further adaptive mutations, and so on. Our study provides a framework for testing this hypothesis by using deep sequencing to analyze avian influenza virus populations within humans, followed by phenotypic characterization in the laboratory.

## Acknowledgments

We thank Susan Watson for editing the manuscript and Eileen A. Maher, Sarmila Basnet, Alexander I. Karasin, Peter Jester, Robert Presler Jr., and Kelly Moore for support. We also thank Yohei Watanabe for technical advice.

This work was supported by a US National Institutes of Health, National Institute of Allergy and Infectious Diseases–funded research grant (R01 AI069274); by the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Science, Sports, and Technology of Japan; by the Japan Agency for Medical Research and Development; by Leading Advanced Projects for Medical Innovation from the Japan Agency for Medical Research and Development; and by grants-in-aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports, and Technology of Japan (nos. 16H06429, 16K21723, and 16H06434). Further support came from a National Institute of Allergy and Infectious Diseases–funded grant (R01 AI114730) to J.C.P. Additional support came from R01 AI125392 to T.C.F.

Y.K. and G.N. are cofounders of FluGen. Y.K. has received royalties from MedImmune and grant support from Chugai Pharmaceuticals, Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Denka Seiken Co. Ltd., and Tsumura and Co.

## About the Author

Dr. Imai is a research associate in the Department of Pathobiological Sciences at the University of Wisconsin–Madison, Madison, Wisconsin, USA. His research interests include the prevention and control of avian and human influenza viruses.

## References



1. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). *N Engl J Med*. 2005;352:333–40. <http://dx.doi.org/10.1056/NEJMoa044021>
2. Wang H, Feng Z, Shu Y, Yu H, Zhou L, Zu R, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. *Lancet*. 2008;371:1427–34. [http://dx.doi.org/10.1016/S0140-6736\(08\)60493-6](http://dx.doi.org/10.1016/S0140-6736(08)60493-6)
3. Nguyen TH, Farrar J, Horby P. Person-to-person transmission of influenza A (H5N1). *Lancet*. 2008;371:1392–4. [http://dx.doi.org/10.1016/S0140-6736\(08\)60494-8](http://dx.doi.org/10.1016/S0140-6736(08)60494-8)
4. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. *Nature*. 2012;486:420–8. <http://dx.doi.org/10.1038/nature10831>
5. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. *Science*. 2012;336:1534–41. <http://dx.doi.org/10.1126/science.1213362>
6. Chen LM, Blixt O, Stevens J, Lipatov AS, Davis CT, Collins BE, et al. In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. *Virology*. 2012;422:105–13. <http://dx.doi.org/10.1016/j.virol.2011.10.006>
7. Zhang Y, Zhang Q, Kong H, Jiang Y, Gao Y, Deng G, et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. *Science*. 2013;340:1459–63. <http://dx.doi.org/10.1126/science.1229455>
8. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. *Microbiol Rev*. 1992;56:152–79.
9. Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, James SL, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. *Science*. 2012;336:1541–7. <http://dx.doi.org/10.1126/science.1222526>
10. Reperant LA, Kuiken T, Grenfell BT, Osterhaus AD. The immune response and within-host emergence of pandemic influenza virus. *Lancet*. 2014;384:2077–81. [http://dx.doi.org/10.1016/S0140-6736\(13\)62425-3](http://dx.doi.org/10.1016/S0140-6736(13)62425-3)
11. Wilker PR, Dinis JM, Starrett G, Imai M, Hatta M, Nelson CW, et al. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. *Nat Commun*. 2013;4:2636. <http://dx.doi.org/10.1038/ncomms3636>
12. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. *Proc Natl Acad Sci U S A*. 1999;96:9345–50. <http://dx.doi.org/10.1073/pnas.96.16.9345>
13. Totani K, Kubota T, Kuroda T, Murata T, Hidari KI, Suzuki T, et al. Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. *Glycobiology*. 2003;13:315–26. <http://dx.doi.org/10.1093/glycob/cwg032>
14. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. *Nature*. 2006;444:378–82. <http://dx.doi.org/10.1038/nature05264>
15. Walther T, Karamanska R, Chan RW, Chan MC, Jia N, Air G, et al. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. *PLoS Pathog*. 2013;9:e1003223. <http://dx.doi.org/10.1371/journal.ppat.1003223>
16. Xu R, McBride R, Nycholat CM, Paulson JC, Wilson IA. Structural characterization of the hemagglutinin receptor specificity from the 2009 H1N1 influenza pandemic. *J Virol*. 2012;86:982–90. <http://dx.doi.org/10.1128/JVI.06322-11>
17. Watanabe Y, Ibrahim MS, Ellakany HF, Kawashita N, Mizuike R, Hiramatsu H, et al. Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. *PLoS Pathog*. 2011;7:e1002068. <http://dx.doi.org/10.1371/journal.ppat.1002068>
18. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, et al. H5N1 virus attachment to lower respiratory tract. *Science*. 2006;312:399. <http://dx.doi.org/10.1126/science.1125548>
19. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene*. 1991;108:193–9. [http://dx.doi.org/10.1016/0378-1119\(91\)90434-D](http://dx.doi.org/10.1016/0378-1119(91)90434-D)
20. Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y. Compatibility among polymerase subunit proteins is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses. *J Virol*. 2008;82:11880–8. <http://dx.doi.org/10.1128/JVI.01445-08>
21. Fan S, Macken CA, Li C, Ozawa M, Goto H, Iswahyudi NF, et al. Synergistic effect of the PDZ and p85 $\beta$ -binding domains of the NS1 protein on virulence of an avian H5N1 influenza A virus. *J Virol*. 2013;87:4861–71. <http://dx.doi.org/10.1128/JVI.02608-12>
22. Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, et al. The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. *PLoS Pathog*. 2010;6:e1001106. <http://dx.doi.org/10.1371/journal.ppat.1001106>

23. Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, et al. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. *PLoS Pathog.* 2012;8:e1002916. <http://dx.doi.org/10.1371/journal.ppat.1002916>
24. Paulson JC, de Vries RP. H5N1 receptor specificity as a factor in pandemic risk. *Virus Res.* 2013;178:99–113. <http://dx.doi.org/10.1016/j.virusres.2013.02.015>
25. Linster M, van Boheemen S, de Graaf M, Schrauwen EJA, Lexmond P, Mänz B, et al. Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus. *Cell.* 2014;157:329–39. <http://dx.doi.org/10.1016/j.cell.2014.02.040>
26. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. *Science.* 2001;293:1840–2. <http://dx.doi.org/10.1126/science.1062882>
27. Hale BG, Randall RE, Ortín J, Jackson D. The multifunctional NS1 protein of influenza A viruses. *J Gen Virol.* 2008;89:2359–76. <http://dx.doi.org/10.1099/vir.0.2008/004606-0>
28. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. *Lancet.* 2004;363:617–9. [http://dx.doi.org/10.1016/S0140-6736\(04\)15595-5](http://dx.doi.org/10.1016/S0140-6736(04)15595-5)
29. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. *Nat Med.* 2002;8:950–4. <http://dx.doi.org/10.1038/nm757>
30. Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, et al., editors. *Fields Virology*. 6th ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1186–243.
31. Gabriel G, Czudai-Matwich V, Klenk HD. Adaptive mutations in the H5N1 polymerase complex. *Virus Res.* 2013;178:53–62. <http://dx.doi.org/10.1016/j.virusres.2013.05.010>
32. Chutinimitkul S, van Riel D, Munster VJ, van den Brand JM, Rimmelzwaan GF, Kuiken T, et al. In vitro assessment of attachment pattern and replication efficiency of H5N1 influenza A viruses with altered receptor specificity. *J Virol.* 2010;84:6825–33. <http://dx.doi.org/10.1128/JVI.02737-09>
33. Naughtin M, Dyason JC, Mardy S, Sorn S, von Itzstein M, Buchy P. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus. *Antimicrob Agents Chemother.* 2011;55:2004–10. <http://dx.doi.org/10.1128/AAC.01773-10>
34. Kongchanagul A, Suptawiwat O, Kanrai P, Uiprasertkul M, Puthavathana P, Auewarakul P. Positive selection at the receptor-binding site of haemagglutinin H5 in viral sequences derived from human tissues. *J Gen Virol.* 2008;89:1805–10. <http://dx.doi.org/10.1099/vir.0.2008/002469-0>
35. Pflug A, Guilligay D, Reich S, Cusack S. Structure of influenza A polymerase bound to the viral RNA promoter. *Nature.* 2014;516:355–60. <http://dx.doi.org/10.1038/nature14008>
36. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected? *Emerg Microbes Infect.* 2012;1:e46. <http://dx.doi.org/10.1038/emi.2012.47>
37. Schneider WL, Roossinck MJ. Genetic diversity in RNA virus quasispecies is controlled by host-virus interactions. *J Virol.* 2001;75:6566–71. <http://dx.doi.org/10.1128/JVI.75.14.6566-6571.2001>

Address for correspondence: Thomas C. Friedrich or Yoshihiro Kawaoka, Department of Pathobiological Sciences, University of Wisconsin, 575 Science Dr, Madison, WI 53711, USA; email: thomasf@primate.wisc.edu or kawaokay@svm.vetmed.wisc.edu

## January 2014: Vaccine-Preventable Diseases

- Severe Fever with Thrombocytopenia Syndrome, Shandong Province, China, 2011
- Genomic Epidemiology of *Vibrio cholerae* O1 Associated with Floods, Pakistan, 2010
- Progenitor “*Mycobacterium canettii*” Clone Responsible for Lymph Node Tuberculosis Epidemic, Djibouti
- A Historical Perspective of Influenza A(H1N2) Virus
- Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan
- Raw Milk Consumption among Patients with Non-Outbreak-related Enteric Infections, Minnesota, USA, 2001–2010
- Genetic Variation of *Vibrio cholerae* during Outbreaks, Bangladesh, 2010–2011
- Population-based Surveillance for Bacterial Meningitis in China, September 2006–December 2009
- Effects of Drinking-Water Filtration on *Cryptosporidium* Seroepidemiology, Scotland



- Epidemiology of Influenza A Virus among Black-headed Gulls, the Netherlands, 2006–2010
- Use of Electronic Death Certificates for Influenza Death Surveillance
- Avian Hepatitis E Virus in Chickens, Taiwan, 2013

<https://wwwnc.cdc.gov/eid/articles/issue/20/1/table-of-contents>

# EMERGING INFECTIOUS DISEASES

# Diversity of Influenza A (H5N1) Viruses in Infected Humans

## Technical Appendix

**Technical Appendix Table 1.** Primer sequences used in this study

vRNA segment	Nucleotide positions of RT-PCR products*	Forward primer		Reverse primer	
		Name	Sequence	Name	Sequence
PB2	1–1784	PB2–1-24F	AGCGAAAGCAGGTCAAATATATTC	PB2–1762–1784R	TTGGGTACCAAGGATTGGAACGG
	532–2341	PB2–532–558F	CCAAATGAAGTGGGAGCTAGAATATTG	PB2–2318–2341R	AGTAGAAACAAGGTCGTTTTTAAA
	167–2277	PB2–167–186F	TGAAATGGATGATGGCAATG	PB2–2258–2277R	CGCTGTCTGGCTGTCAGTAA
PB1	1–1829	PB1–1-18F	AGCGAAAGCAGGCAAACC	PB1–1804–1829R	CGGATATTGTATAGATTTGGTCCTCC
	501–2341	PB1–501–522F	ATCGGGACGGCTAATAGATTTTC	PB1–2317–2341R	AGTAGAAACAAGGCATTTTTTTCACG
	106–2214	PB1–106–125F	CCTCCATACAGCCATGGAAC	PB1–2195–2214R	GAAATCAATTCGTGCGTCAA
PA	1–1668	PA-1–21F	AGCGAAAGCAGGTAATGATCC	PA-1646–1668R	CATGTCTCCTATCTCGAGGACAC
	565–2233	PA-565–587F	GAAATGGCCAGTAGGGGTCTATG	PA-2208–2233R	AGTAGAAACAAGGTACTTTTTTGGAC
	74–2169	PA-74–93F	CGGAAAAGGCAATGAAAGAA	PA-2150–2169R	CAGTGCATGTGTGAGGAAGG
HA <sup>†</sup>	1–1776(1779) <sup>‡</sup>	HA-1–21F-T	AGCAAAAGCAGGGGTTCATC	HA-1754–1776R-T	AGTAGAAACAAGGGTGTTTTTAECTA
	1–1776	HA-1–21F-T	AGCAAAAGCAGGGGTTCATC	HA-1754–1776R-C	AGTAGAAACAAGGGTGTTTTCAECTA
	1–1776	HA-1–21F-C	AGCAAAAGCAGGGGTTCATC	HA-1754–1776R-T	AGTAGAAACAAGGGTGTTTTTAECTA
	96–793	HA-96–115F	ACCATGCAAACAACCTCGCAC	HA-774–793R	GATTGCATCGTCCGGTTTTA
NP	1–1565	NP-1–24F	AGCAAAAGCAGGGTAGATAATCAC	NP-1541–1565R	AGTAGAAACAAGGGTATTTTTCTTTA ATTG
	51–1487	NP-51–70F	GTCTCAAGGCACCAAACGAT	NP-1468–1487R	ATGTCAAAGGAAGGCACGAT
NS	1–875	NS-1–23F	AGCAAAAGCAGGGTGACAAAAC	NS-852–875R	AGTAGAAACAAGGGTGTTTTTTAT
	83–772	NS-83–102F	CAAACGATTTGCAGACCAAG	NS-752–772R	TCTGTTCGAAGCTGTTTTCTG

\*All numbers listed refer to positive-sense orientation.

<sup>†</sup>To amplify the full-length HA segment, we used three different combinations of primers, based on the predetermined terminal sequences of the vRNA segments of each virus: HA-1–21F-T/HA-1754–1776R-T were used for UT3040I/II, UT31312I/II/III, UT31394I/II, and UT36250I/II; HA-1–21F-T/HA-1754–1776R-C were used for UT31413I/II; and HA-1–21F-C/HA-1754–1776R-T were used for UT36282I/II and UT36285I/II.

<sup>‡</sup>The HA genes of UT3040I and UT36250I are 1779 nt in length because of three additional nucleotides at the multibasic cleavage site.

**Technical Appendix Table 2.** Summary of nonsynonymous and synonymous single-nucleotide polymorphisms (SNPs) detected at  $\geq 1\%$

Virus isolate	Date of sample collection	Viral RNA segment											
		PB2		PB1		PA		HA		NP		NS	
		N*	S†	N	S	N	S	N	S	N	S	N	S
UT3040I	2004 Jan 6	8	2	6	10	10	0	1	4	1	3	1	0
UT3040II	2004 Jan 7	NA‡	NA	0	0	0	1	1	0	NA	NA	0	0
UT31312I	2007 Jul 25	3	2	0	1	0	0	1	3	1	0	0	0
UT31312II	2007 Jul 26	4	1	0	0	0	0	5	0	1	0	1	0
UT31312III	2007 Jul 25	4	0	0	0	0	0	6	2	0	1	0	0
UT31394I	2008 Jan 17	12	3	6	10	5	3	11	8	5	0	2	1
UT31394II	2008 Jan 17	6	1	3	2	4	0	4	3	4	0	1	0
UT31413I	2008 Feb 13	0	0	9	2	5	5	1	0	6	3	4	0
UT31413II	2008 Feb 13	0	1	0	3	0	1	5	8	0	0	2	0
UT36250I	2010 Mar 10	12	8	9	7	11	4	14	1	7	0	3	0
UT36250II	2010 Mar 11	0	0	NA	NA	NA	NA	6	2	NA	NA	1	0
UT36282I	2010 Apr 1	3	3	2	5	1	2	3	2	2	1	0	0
UT36282II	2010 Apr 3	2	2	1	3	2	2	5	7	3	3	8	4
UT36285I	2010 Apr 4	0	1	NA	NA	0	1	0	0	0	0	0	0
UT36285II	2010 Apr 8	3	2	NA	NA	3	2	NA	NA	1	0	0	0

\*N, nonsynonymous single-nucleotide polymorphism; NA, not applicable because of low sequence coverage; S, synonymous single-nucleotide polymorphism.

**Technical Appendix Table 3.** Genetic variability among influenza A(H5N1) virus samples isolated from infected persons, northern Vietnam, 2004–2010

Viral protein, aa position	Virus isolate	Major variant in sample		Minor variant in sample		Consensus of top 25 blastn hits of avian H5 viruses†
		Amino acid	Percentage	Amino acid	Percentage	
<b>PB2</b>						
15	UT36250I	R	69.7	C	26.9	R
	UT36250II	C	100.0	R	0.0	R
<b>627</b>	UT3040I	K	92.6	E	7.4	E
	UT31312I	E	67.9	K	32.1	E
	UT31312II	E	72.1	K	27.9	E
	UT31312III	K	64.7	E	35.3	E
	UT31394I	E	50.5	K	49.5	E

Viral protein, aa position	Virus isolate	Major variant in sample		Minor variant in sample		Consensus of top 25 blastn hits of avian H5 viruses†
		Amino acid	Percentage	Amino acid	Percentage	
	UT31394II	K	51.7	E	48.3	E
	UT36250I	E	74.3	K	25.7	E
<b>PB1</b>						
123	UT36250I	T	95.0	A	5.0	T
213	UT36282I	N	92.3	D	7.7	N
	UT36282II	N	94.4	D	5.6	N
254	UT31394I	F	94.3	L	5.7	F
	UT31394II	F	93.2	L	6.8	F
538	UT31394II	D	84.9	G	15.1	D
598	UT36250I	L	68.8	P	31.2	L
<b>PA</b>						
85	UT3040I	T	95.2	M	4.8	T
	UT3040II	M	100.0	T	0.0	T
90	UT3040I	V	94.8	M	5.2	V
142	UT3040I	K	87.2	E	12.8	K
260	UT31413I	F	94.5	S	5.5	F
325	UT31413I	P	94.9	S	5.1	P
387	UT3040I	V	94.2	I	5.8	V
417	UT3040I	L	91.4	V	8.6	L
	UT3040II	V	100.0	L	0.0	L
651	UT31394I	A	89.0	S	11.0	A
	UT31394II	A	90.1	S	9.9	A
<b>HA<sup>‡</sup></b>						
54(+1) <sup>§</sup>	UT31394I	E	66.5	D	33.5	D
	UT31394II	D	54.5	E	45.5	D
67	UT31394II	A	91.7	T	8.3	A
92	UT31312II	N	60.7	K	39.3	N
<b>138</b>	UT3040I	A	94.7	V	5.3	A
	UT36250I	A	72.0	V	28.0	A
	UT36250II	A	80.2	V	19.8	A
	UT36282I	A	93.9	V	6.1	A
	UT36282II	A	94.7	V	5.3	A
<b>186</b>	UT3040II	N	88.6	K	11.4	N

Viral protein, aa position	Virus isolate	Major variant in sample		Minor variant in sample		Consensus of top 25 blastn hits of avian H5 viruses†
		Amino acid	Percentage	Amino acid	Percentage	
	UT31312III	N	86.8	K	13.2	N
203	UT31312III	S	85.4	P	14.6	S
207	UT31394I	S	79.0	T	21.0	S
	UT31394II	S	52.8	T	47.2	S
226	UT36250II	Q	86.0	K	14.0	Q
456	UT31312III	M	54.9	R	45.1	R
486	UT31413II	Y	94.7	H	5.3	Y
511	UT31413I	T	90.4	I	9.6	T
<b>NP</b>						
77	UT31394I	R	92.3	K	7.7	R
	UT31394II	R	79.1	K	20.9	R
430	UT36282II	A	92.5	V	7.5	T <sup>#</sup>
454	UT31394I	E	91.2	G	8.8	E
	UT31394II	E	79.0	G	21.0	E
<b>NS1</b>						
124	UT36250I	I	85.8	M	14.2	I
	UT36250II	I	78.2	M	21.8	I

\*Listed are single-nucleotide polymorphisms detected in 5%–50% of the sequence reads directly derived from viral RNAs (single-nucleotide polymorphisms detected in more than half of the sequence reads were considered the major variant); also listed is 1 variant (at position 85 of PA) that was found in <5% of the reads at the first sampling time, but increased substantially in frequency at the second sampling time. HA, hemagglutinin; NP, nucleocapsid; NS, nonstructural; PA, polymerase acidic; PB, polymerase basic. Boldface indicates amino acid changes detected in samples isolated from several patients.




















†To compare the amino acid sequences of the human H5N1 virus isolates tested here with those of closely related avian H5 viruses, each human H5N1 viral gene sequence was first BLASTn searched with avian H5N1 viruses. Then, the consensus amino acids of the top 25 BLASTn hits were retrieved.

‡For HA, the numbers refer to the amino acid positions in mature H3 HA.

§After position 54, H5 HA proteins possess an additional amino acid not found in H3 HA proteins.

#For the top 5 BLASTn (<https://www.fludb.org/brc/blast.spg?method=ShowCleanInputPage&decorator=influenza>) hits (i.e., the most closely related viruses), the consensus amino acid at this position is A.

**Technical Appendix Table 2. List of sialosides used for glycan arrays**

Glycan #	Common Name	Structure
1	Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
2	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
3	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
4	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
5	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
6	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
7	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
8	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -Asn-Ser-Thr-NH <sub>2</sub>	
9	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)]-Man $\alpha$ (1-6)}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-Lys-NH <sub>2</sub>	
10	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)]-Man $\alpha$ (1-6)}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
11	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)6-O-sulfo-GlcNAc $\beta$ -propyl-NH <sub>2</sub>	
12	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-6-O-sulfo-GlcNAc $\beta$ -propyl-NH <sub>2</sub>	
13	NeuAc $\alpha$ (2-3)6-O-sulfo-Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
14	NeuAc $\alpha$ (2-3)6-O-sulfo-Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ -propyl-NH <sub>2</sub>	
15	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)6-O-sulfo-GlcNAc $\beta$ -propyl-NH <sub>2</sub>	
16	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)Glc $\beta$ -ethyl-NH <sub>2</sub>	
17	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
18	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
19	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	



Glycan #	Common Name	Structure
20	NeuAc $\alpha$ (2-3)GalNAc $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
21	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
22	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
23	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
24	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GalNAc $\beta$ (1-3)Gal $\alpha$ (1-4)Gal $\beta$ (1-4)Glc $\beta$ -ethyl-NH <sub>2</sub>	
25	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
26	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
27	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
28	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
29	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
30	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
31	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)[GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
32	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
33	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
34	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
35	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
36	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	

Glycan #	Common Name	Structure
37	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
38	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
39	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
40	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
41	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
42	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
43	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
44	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
45	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
46	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
47	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	

Glycan #	Common Name	Structure
48	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
49	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
50	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
51	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)GlcNAc $\beta$ (1-3)] Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
52	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)] Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
53	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
54	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
55	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
56	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
57	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	

Glycan #	Common Name	Structure
58	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
59	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
60	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
61	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
62	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
63	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	

Glycan #	Common Name	Structure
64	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
65	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
66	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
67	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
68	Gn/3'SLN/3'SLN-TriN	
69	NeuAc $\alpha$ (2-3)[GalNAc $\beta$ (1-4)]-Gal $\beta$ (1-4)Glc $\beta$ -ethyl-NH <sub>2</sub>	
70	NeuAc $\alpha$ (2-3)[GalNAc $\beta$ (1-4)]-Gal $\beta$ (1-4)Glc $\beta$ -ethyl-NH <sub>2</sub>	
71	Gal $\beta$ (1-3)GalNAc $\beta$ (1-4)[NeuAc $\alpha$ (2-3)]-Gal $\beta$ (1-4)Glc $\beta$ -ethyl-NH <sub>2</sub>	

Glycan #	Common Name	Structure
72	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ -propyl-NH <sub>2</sub>	
73	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-3)[Fuc $\alpha$ (1-4)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
74	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
75	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
76	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
77	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
78	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-6)-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
79	NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-3)Gal $\beta$ (1-4)[Fuc $\alpha$ (1-3)]-GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-(Lys-Thr)NH <sub>2</sub>	
80	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)(6S)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
81	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)6-O-sulfo-GlcNAc $\beta$ -propyl-NH <sub>2</sub>	
82	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)Glc $\beta$ -ethyl-NH <sub>2</sub>	
83	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
84	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
85	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
86	NeuAc $\alpha$ (2-6)GalNAc $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
87	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	

Glycan #	Common Name	Structure
88	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
89	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
90	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
91	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
92	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
93	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
94	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
95	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
96	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ (1-6)[Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
97	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
98	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-3)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
99	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
100	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
101	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	



Glycan #	Common Name	Structure
102	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
103	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
104	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
105	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
106	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
107	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
108	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)]-GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
109	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
110	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)GalNAc $\alpha$ -Thr-NH <sub>2</sub>	
111	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)]Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	
112	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-3)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-3)GlcNAc $\beta$ (1-3)]Gal $\beta$ (1-4)GlcNAc $\beta$ -ethyl-NH <sub>2</sub>	




Glycan #	Common Name	Structure
113	Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
114	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
115	GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
116	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
117	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
118	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
119	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -Asn-NH <sub>2</sub>	
120	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
121	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	

Glycan #	Common Name	Structure
122	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
123	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
124	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
125	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-6)]-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
126	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
127	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	


Glycan #	Common Name	Structure
128	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
129	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
130	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
131	NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)Man $\alpha$ (1-3){NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-2)[NeuAc $\alpha$ (2-6)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-3)Gal $\beta$ (1-4)GlcNAc $\beta$ (1-6)Man $\alpha$ (1-6)]}-Man $\beta$ (1-4)GlcNAc $\beta$ (1-4)[Fuc $\alpha$ (1-6)]-GlcNAc $\beta$ -(Lys-Val-Ala)Asn-Lys-Thr-NH <sub>2</sub>	
132	LN/6'SLN/6'SLN-TriN	
133	6'SLNLN/6'SLN/6'SLN-TriN	

Glycan #	Common Name	Structure
<b>134</b>	6'SLN/LeX/LeX-TriN	 <p>The structure for 6'SLN/LeX/LeX-TriN is a branched N-glycan. It features a core fucose (purple diamond) attached to the first mannose (yellow circle) via an α1-6 linkage. The backbone consists of a galactose (green circle) linked β1-4 to a glucose (blue square), which is linked β1-4 to another glucose (blue square). A second mannose (yellow circle) is attached to the second glucose via an α1-6 linkage. A sialic acid (red triangle) is attached to the second mannose via an α2,6 linkage. A second galactose (green circle) is attached to the second glucose via an α1-6 linkage. A third mannose (yellow circle) is attached to the third glucose via an α1-6 linkage. A sialic acid (red triangle) is attached to the third mannose via an α2,6 linkage.</p>
<b>135</b>	6'SLNLN/LeX/LeX-TriN	 <p>The structure for 6'SLNLN/LeX/LeX-TriN is similar to 134 but includes an additional mannose. It features a core fucose (purple diamond) attached to the first mannose (yellow circle) via an α1-6 linkage. The backbone consists of a galactose (green circle) linked β1-4 to a glucose (blue square), which is linked β1-4 to another glucose (blue square). A second mannose (yellow circle) is attached to the second glucose via an α1-6 linkage. A sialic acid (red triangle) is attached to the second mannose via an α2,6 linkage. A second galactose (green circle) is attached to the second glucose via an α1-6 linkage. A third mannose (yellow circle) is attached to the third glucose via an α1-6 linkage. A sialic acid (red triangle) is attached to the third mannose via an α2,6 linkage. A fourth mannose (yellow circle) is attached to the fourth glucose via an α1-6 linkage. A sialic acid (red triangle) is attached to the fourth mannose via an α2,6 linkage.</p>


**Technical Appendix Figure 1.** List of sialosides used for glycan arrays. The first column indicating the glycan number is colored as follows: gray, glycan without sialic acid; blue, glycan with sialic acid in an α2,3-linkage; red, glycan with sialic acid in an α2,6-linkage.




**Technical Appendix Figure 2.** Deep-sequencing reveals H5N1 influenza sequence variation among humans infected with H5N1 viruses. The PB2, PB1, PA, HA, NP, and NS vRNAs were amplified from throat swabs or tracheal aspirates and deep-sequenced. Single-nucleotide polymorphisms (SNPs) detected in  $\geq 1\%$  of sequence reads were identified by comparing sequence reads with the consensus sequence assembled for each sample. Grey bars indicate gene regions with insufficient sequence coverage ( $< 100$  sequence reads) to call variants. Squares and circles indicate synonymous and nonsynonymous SNPs, respectively. SNP frequencies are represented as a heatmap with synonymous and nonsynonymous mutations represented in blue and red, respectively. Since SNPs were called relative to their consensus nucleotide, the maximum frequency of each SNP is  $< 50\%$ .



**Technical Appendix Figure 3.** Effect of amino acid variations in HA on tissue binding ability. Binding of viruses to human trachea sections, on which  $\alpha$ 2,6-linked sialic acids are present, was assessed. If two isolate numbers are listed (such as CA04/UT3040I/II), we tested the major sequence variant, which is identical between the two samples. FITC-labeled viruses were incubated with deparaffinized tissue sections and virus-tissue binding was detected by means of immunohistochemistry. Signals were observed as a dark-red color; images were obtained by using the upright microscope, Axio Imager.A2 (Zeiss, Oberkochen, Germany) with a 100 X objective lens. Nuclei were counterstained with Mayer's hematoxylin (Sigma Aldrich, St. Louis, MO, USA). CA04/K173 virus was used as a control.



**Technical Appendix Figure 4.** Confirmation of virus binding specificity to sialic acids. To confirm virus binding specificity to sialic acids, we pretreated tracheal tissues with  $\alpha(2\rightarrow3,6,8,9)$  neuraminidase from *Arthrobacter ureafaciens* (Sigma Aldrich), which removes terminal sialic acids. Binding of viruses to the pretreated sections was assessed. If two isolate numbers are listed (such as CA04/UT3040I/II), we tested the major sequence variant, which is identical between the two samples. FITC-labeled viruses were incubated with the pretreated tissue sections and virus-tissue binding was detected by means of immunohistochemistry. Nuclei were counterstained with Mayer's hematoxylin (Sigma Aldrich).



**Technical Appendix Figure 5.** Effect of an amino acid variation in NS1 on interferon antagonistic properties. (A) Effect of NS1 on interferon production. 293T cells were transfected with a plasmid encoding the wild-type or mutant NS gene and with a plasmid encoding the firefly luciferase gene under the control of the interferon $\beta$  promoter. An empty vector and a plasmid expressing GFP served as negative controls. A plasmid expressing the human influenza A virus K173 NS gene was used as a positive control. Twenty-four hours after transfection, cells were infected with  $10^6$  fluorescence-forming units of Sendai virus to stimulate interferon synthesis. The ability of NS1 to interfere with interferon production was measured 48 h later. (B) Effect of NS1 on interferon signaling. Cells were transfected with control plasmids or plasmids encoding the wild-type or mutant NS gene, and with a plasmid expressing luciferase under the control of an interferon-regulated stimulatory element (ISRE). The cells were incubated for 24 h and then treated with 100 units of human interferon $\beta$  for 6 h. In both assays, firefly luciferase activities were measured by using Luciferase Assay Reagent II (Promega). The experiments (each in triplicate) were repeated twice independently. Mean relative interferon antagonistic activities with standard deviations are shown. The activity of cells transfected with the pCAGGS empty vector (nontreated with Sendai virus or nonincubated with interferon $\beta$ ) was set to 100%. The asterisks indicate a significant difference in interferon antagonistic activities between the 'empty' vector, UT36250I-NS1, and/or UT36250I-NS1–124M (\*\* $p < 0.01$ ; one-way ANOVA followed by Tukey's post-hoc test; N.S.: not significant).